CD38 and hereditary sensory and autonomic neuropathy: Interestingly, the ratio of CD38 to complement inhibitory proteins (CIP) was subsequently demonstrated to better correlate with antitumor efficacy of daratumumab than using either CD38 or CIP expression alone (187).